3M's $7.35 Billion AFFF Deal Resets the PFAS Settlement Playbook
3M disclosed via an SEC 8-K on November 3 that it has reached a resolution covering roughly 99 percent of pending AFFF personal injury claims in MDL 2873 before the District of South Carolina. The deal touches an estimated 115,000 to 120,000 plaintiffs and carries a nominal value of $7.35 billion, with a present value closer to $5.8 billion paid out between 2026 and 2034.
3M admits no liability. The company has committed to an initial $50 million payment in 2026, with the balance following a points-based injury matrix that firms with PFAS inventory should expect to see modeled on kidney cancer, ulcerative colitis, and thyroid disease tiers common to prior mass tort allocations.
This is distinct from the earlier $10.3 billion municipal water-system resolution; this track pays individual claimants directly. Firms with AFFF intake should confirm claims-administrator selection and matrix weighting now, since allocation disputes in comparable PFAS and opioid programs have consumed months of post-settlement litigation on their own.
Firms holding AFFF inventory should audit injury-tier documentation before claims administration opens, not after.
St. Louis Jury's $37.04 Million Verdict Signals Punitive Exposure in Delayed-Diagnosis Cases
Missouri Lawyers Media's November 4 re-report of an August 25 St. Louis County verdict put total damages in Birkel v. Gheith at $37.04 million: $7.04 million compensatory, $20 million punitive against Dr. Gheith individually, and $10 million punitive against Interventional Pain Institute.
The theory centered on failure to order a timely thoracic MRI despite worsening neurological symptoms. Plaintiff's counsel argued the delay allowed a spinal mass to progress to irreversible tissue degeneration and partial paralysis, a fact pattern that spine and neurology malpractice practices will likely cite in similar delayed-imaging claims.
Defense has filed a motion to stay judgment. The roughly 4.3-to-1 punitive-to-compensatory ratio against the physician sits above the single-digit guideposts federal due process doctrine typically tolerates, making the stay motion and any post-trial remittitur fight worth tracking for appellate counsel statewide.
The punitive ratio here is high enough that a remittitur ruling, not the verdict itself, will likely set the real precedent.
California's SB 623 Caps Lien-Based Billing at 70th Percentile FAIR Health Rates
Civil Code section 3333.9, chaptered June 25 and effective January 1, 2027, caps recoverable past medical expenses in rideshare and transportation network company claims at the 70th percentile of FAIR Health billed charges. Holland & Knight and Advocate Magazine both confirm this is the first California statute to codify a Pebley-limiting benchmark for a specific tort category.
The statute also opens broad discovery into financial relationships between referring attorneys and lien-based treatment clinics, a provision that will matter well beyond rideshare defense bars once discovery requests start circulating in adjacent practice areas.
Outside TNC claims, Pebley v. Santa Clara Organics still controls: lien-treated plaintiffs may introduce full billed amounts as evidence of reasonable value, subject to defense challenge under Howell v. Hamilton Meats and CACI 3903A's reasonable-cost instruction. Qaadir v. Figueroa keeps attorney referrals to lien doctors admissible at trial.
For lien-based medical providers, the message is operational rather than legal. Billing that can be benchmarked against FAIR Health data, with clean documentation of referral and treatment timelines, survives the Howell challenge; billing that cannot will draw discovery on the attorney-clinic relationship even outside rideshare cases.
Lien-based providers outside the rideshare carve-out should start benchmarking rates against FAIR Health now, not after a defense discovery request arrives.
New Jersey and Georgia Rulings Address Informed Consent and Liability Allocation
The New Jersey Law Journal reported on November 3 a $7.5 million award to a Kasowitz partner against a physician who failed to disclose that a diagnostic test had shown lung cancer. The theory rested on informed consent and failure to disclose a diagnostic result, independent of any claim the underlying treatment itself was negligent.
In Georgia, the Court of Appeals affirmed on October 16 a trial court's refusal to let a surgeon shift liability share to a co-defendant physician in a $6.8 million medical malpractice settlement, reinforcing the state's indivisibility doctrine for injuries caused across multiple treating providers.
Read together, both rulings narrow defendants' options in multi-provider cases: disclosure failures create standalone liability in New Jersey regardless of treatment quality, and Georgia defendants cannot dilute a settlement by pointing at co-defendants after the fact.
Multi-defendant malpractice counsel in both states should plead disclosure and treatment theories separately rather than relying on one to cover the other.
ERISA Lien Resistance and Platform Liability MDLs Bear Watching Into Year-End
The Daily Journal reported September 4 that self-funded ERISA plan administrators are increasingly refusing proportionate-fee reductions in PI settlements, leaning on federal preemption even where Montanile v. Board of Trustees left room for proportionate-reduction arguments in limited circumstances.
For medical providers coordinating lien resolution alongside ERISA subrogation, plan-specific reimbursement language and notice timing now matter more than settlement amount alone. Billing departments should pull plan documents at intake rather than at the back end of a case, when leverage to negotiate is already gone.
Separately, MDL-3047 in the Northern District of California saw a Los Angeles jury find Meta and YouTube liable on a personal injury track in March, with reported awards ranging $3 million to $6 million across conflicting trade reports. More than 3,800 cases remain pending, and a $17 billion state AG consent judgment does not resolve individual claims.
Providers and firms managing ERISA-governed liens should treat plan language review as a day-one task, not a settlement-week scramble.
Unverified This Week: Montgomery v. Caribe Transport and the Freight-Broker Question
Multiple trade outlets reported on May 14 that the U.S. Supreme Court held the Federal Aviation Administration Authorization Act no longer shields freight brokers from negligent-carrier-selection suits. The primary docket has not been independently confirmed as of this writing.
If accurate, the ruling reopens a broker-liability theory that trucking PI firms largely shelved after years of adverse circuit splits on FAAAA preemption, with direct implications for any pending claims against brokers who placed loads with unsafe carriers.
Counsel with pending freight-broker liability claims should pull the Caribe Transport docket directly before citing it in any filing.